Researchers at the Dana-Farber Cancer Institute in Boston, Massachusetts, have developed a new blood testing method that could change the way multiple myeloma and its preceding conditions are diagnosed and monitored. The technique is based on single-cell sequencing and is a non-invasive method for diagnosing and monitoring multiple myeloma, bypassing the need for painful bone marrow biopsies.

Multiple myeloma can be preceded by other conditions, including monoclonal gammopathy of undetermined significance or smoldering multiple myeloma. Multiple myeloma is often diagnosed late. Once it progresses, symptoms such as anemia, bone pain, kidney problems, and infections can arise. While multiple myeloma is the third most common blood cancer, it is still relatively rare, occurring between

See Full Page